Wellington Management Group LLP grew its position in Immatics (NASDAQ:IMTX - Free Report) by 1.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 9,681,183 shares of the company's stock after buying an additional 144,549 shares during the period. Wellington Management Group LLP owned 8.11% of Immatics worth $110,462,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Quarry LP bought a new stake in Immatics during the 2nd quarter worth about $99,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Immatics in the 3rd quarter valued at $114,000. Forefront Analytics LLC acquired a new position in Immatics in the second quarter valued at about $139,000. AlphaCentric Advisors LLC raised its position in shares of Immatics by 14.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company's stock valued at $232,000 after acquiring an additional 2,500 shares during the period. Finally, Algert Global LLC bought a new position in Immatics during the 2nd quarter worth approximately $242,000. Institutional investors own 64.41% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the stock. Bank of America reduced their price target on shares of Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, November 19th. The Goldman Sachs Group raised Immatics to a "strong-buy" rating in a research report on Monday, November 25th. Piper Sandler started coverage on Immatics in a research report on Monday, October 7th. They issued an "overweight" rating and a $19.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a research note on Thursday, September 5th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Immatics has a consensus rating of "Buy" and a consensus target price of $16.67.
Check Out Our Latest Analysis on Immatics
Immatics Price Performance
NASDAQ:IMTX traded down $0.23 during trading hours on Tuesday, reaching $7.55. 402,168 shares of the stock were exchanged, compared to its average volume of 498,220. The stock has a market cap of $901.14 million, a PE ratio of -11.52 and a beta of 0.74. Immatics has a twelve month low of $7.46 and a twelve month high of $13.77. The firm has a 50 day moving average of $9.02 and a 200 day moving average of $10.93.
About Immatics
(
Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Recommended Stories
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
